Objectives: Penetration of antibiotics into synovial fluid is crucial to combat septic arthritis efficiently. Since linezolid may be used for treatment of septic arthritis when methicillin-resistant bacterial strains are suspected, we investigated its target-site concentrations in synovial fluid.
Introduction
Bacterial joint infection, i.e. septic arthritis, is one of the most severe problems in trauma and orthopaedic surgery. Immediate treatment comprising surgical pus evacuation by either arthroscopy or open joint surgery and systemic antibiotic treatment is indicated. 1 Septic arthritis is associated with substantial morbidity and mortality; hence, inadequate or deferred treatment may result in irreversible joint destruction and mortality rates as high as 11%-50%. 2 Generally, septic arthritis is most frequent in elderly people, followed by young children. After arthroscopy, septic arthritis occurs in ,1%. In all age groups, the most frequent causative pathogens isolated are Staphylococcus aureus and CoNS (e.g. Staphylococcus epidermidis) followed by other Gram-positive bacteria, including streptococci. 2, 3 Generally, empirical antimicrobial treatment must include substances active against staphylococci and other common Gram-positive bacteria. 3 Since the introduction of broad-spectrum antibiotics, the rate of bacteria resistant to conventional antibiotics has substantially increased. 4 In terms of bacterial arthritis in some studies up to 50% of all staphylococci isolated from osteoarticular infections were reported to be resistant to methicillin and other b-lactam antibiotics. 5 Usually infections with MDR staphylococci are treated with glycopeptide antibiotics, i.e. vancomycin or teicoplanin, which is also reflected by relevant guidelines. 3, 6 Though, recent reports show increasing numbers of bacterial strains resistant to glycopeptide antibiotics. 7, 8 Particularly, several reports of treatment failure in septic arthritis treated with vancomycin (in combination with other antibiotics) were published during the last decade. 9, 10 Teicoplanin as a treatment alternative is highly bound to plasma proteins, which might limit its penetration into tissues, 11, 12 making patients at risk of inefficient drug concentrations at the target site.
The emergence of glycopeptide-resistant bacteria necessitates the use of new antibiotics for which only limited data are available on their use in bacterial arthritis. One of these antibiotics is linezolid, the first representative of the oxazolidinone group. It is approved for the treatment of community-acquired and nosocomial pneumonia, as well as complicated skin and skinstructure infections. Moreover, linezolid has been shown to penetrate well into different compartments of the human body and has excellent activity against MRSA, even beyond vancomycin resistance. 13, 14 In addition, septic arthritis is often treated medically over many weeks, hence treatment with antibiotics active against MRSA is usually switched from intravenous to oral formulations, which is often challenging. However, linezolid shows complete bioavailability; therefore, switching to oral administration is feasible and does not require dosage change. 15 Several case reports and case series investigated linezolid in septic arthritis with favourable results, even if treatment was initiated after or because of treatment failure with vancomycin. 14 However, although linezolid showed clinical efficacy in some small case series investigating septic arthritis, high-quality pharmacokinetic data describing local tissue concentrations in synovial fluid are lacking. In agreement with statements of major regulatory authorities in Europe and the USA drug tissue concentrations at the infection site are prerequisites to estimate the drug efficacy at the infection site and may differ profoundly from drug plasma concentrations. [16] [17] [18] Therefore, this study set out to measure concentrations of linezolid in plasma, muscle tissue and synovial fluid by use of microdialysis (MD) after a single intravenous infusion of linezolid in patients undergoing elective knee arthroscopy for meniscal repair or crucial ligament reconstruction.
Patients and methods

Ethics
This open-labelled, single-centre Phase 1 study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Prior to initiation of the study the ethics committee of the Medical University of Vienna reviewed the study protocol and the informed consent form and granted approval (EK-1063/2012). All subjects provided written informed consent before study inclusion.
Study population
The study population included 10 male and female subjects above 18 years without clinically relevant medical history except that subjects had to undergo elective knee arthroscopy for repair of meniscus or cruciate ligament damage. The screening evaluation included a physical examination, including body weight, vital signs, blood laboratory tests, urine analysis and a 12-lead electrocardiography. Female subjects had to perform a urine pregnancy test if of childbearing age. Subjects were excluded if they had a history of clinically relevant disease, had clinical significant abnormal findings at the screening examination (including laboratory tests), had a contraindication to take linezolid, were using monoamine oxidase inhibitors, were pregnant or were receiving any investigational drug within 30 days prior to inclusion in the study.
Study medication
Linezolid (Zyvox V R 600 mg; Pfizer Europe GmbH, Vienna, Austria) was diluted in 250 mL of 0.9% saline solution and administered over 30 min by use of an automatic infusion pump. After completion of the study drug infusion a further 100 mL of physiological saline solution was administered over the same infusion line to ensure that the complete 600 mg of linezolid was applied.
Study design
Subjects were admitted to the Department of Trauma Surgery on the day before arthroscopy. Subjects stayed fasting in the trauma surgery ward overnight and on the morning of the study day a peripheral venous catheter was inserted into a vein of each arm. Then arthroscopy according to department standards was performed. Before arthroscopy was finished an MD probe (CMA 63, cut-off 20000 Da; CMA, Sweden) was inserted aseptically into the synovial space of the knee. Thereafter, another MD probe was inserted into the skeletal muscle of the same thigh. The probes were then perfused with saline solution at a flow rate of 2 lL/min by a microinfusion pump (CMA MD pump 107). After the surgery was performed and the patient arrived in the post-anaesthesia care unit linezolid was administered as described above. Linezolid concentrations in muscle tissue and synovial fluid were determined pre-dose and at 0-0.5, 0.5-1, 1-1.5, 1.5-2, 2-2.5, 2.5-3, 3-4, 4-5, 5-6, 6-7 and 7-8 h by MD sampling. After the sampling period, probes were calibrated by retrodialysis before removal.
In addition, linezolid concentrations in plasma were determined at baseline and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7 and 8 h after infusion by drawing blood via the venous catheter of the contralateral arm. Subjects were released from the trauma surgery ward at the discretion of the surgeon. Within 14 days after study drug application a control visit was performed.
MD sampling
Linezolid concentrations in synovial fluid and muscle tissue were evaluated by the MD technique. As described previously, this method is based on the exchange of molecules between the extracellular space of the investigated tissue and an MD probe that is implanted into this tissue. 19, 20 Only free, i.e. non-protein-bound, substances can diffuse across the semipermeable membrane located at the tip of the MD probe and can be collected for subsequent analysis. Calibration of MD probes is performed by the use of retrodialysis. The retrodialysis method relies on the assumption that the diffusion process across the semipermeable membrane is quantitatively equal in both directions, which has been proven in systematic in vitro investigations for linezolid. 21 This implies that the fraction of the interstitial drug concentration that is recovered in the collected microdialysate sample, and is referred to as relative recovery, can be calculated according to the following equation: recovery (%) " 100 # (100 % analyte concentration out /analyte concentration in ). Interstitial linezolid concentrations were calculated as follows: interstitial concentration " 100 % (sample concentration/relative recovery). 20 
Bioanalysis
Linezolid concentrations in plasma and MD samples were analysed using a HPLC method developed and validated at the Institute of Pharmacy, Freie Universit€ at (Berlin, Germany), adapted from previously published methods. 21, 22 A Thermo Scientific Ultimate 3000 HPLC with an HPG-3200SD pump, WPS-3000TSL autosampler, TCC-3000SD column oven and DAD 3000 detector was used for quantification. Separation of linezolid from all 26 concomitantly administered drugs was achieved by a Thermo Fisher Hypersil GOLD Phenyl column (100%4.6 mm, 3 lm) and a Thermo Fisher Phenyl guard column at 35 C using a gradient method with two mobile phases: Milli-Q water with 0.1% trifluoroacetic acid and Milli-Q water with acetonitrile 30:70 (v/v). The flow rate was 2 mL/min and the autosampler was cooled to 4 C to ensure stability of samples. Linezolid was detected after 6.65 min at a wavelength of 251 nm. For one patient, the previously described method was modified due to insufficient selectivity of linezolid from the co-administered, antihypertensive drug urapidil: the gradient was modified and the flow rate was decreased to 1 mL/min; all other parameters were unchanged. MD sample preparation consisted of diluting 30 lL of the sample with 20 lL of acetonitrile. Preparation of plasma samples was performed by adding 400 lL of acetonitrile to 100 lL of sample to Schwameis et al. precipitate the proteins. After centrifugation for 15 min at 13800 g, 300 lL of supernatant was evaporated to dryness. The sample was redissolved in a solution of water and acetonitrile 96:4 (v/v) to obtain the final measurement solution.
Quantification of linezolid was achieved meeting all acceptance criteria of the EMA guideline 23 with good accuracy (inter-and intra-day relative error +11.9% and +15.2% for the lower limit of quantification), precision (inter-and intra-day coefficient of variation 5.9% and 4.9% for the lower limit of quantification) and stability across the entire concentration range of 0.3-25 mg/L for both methods using an injection volume of 20 lL of the samples. Linezolid plasma protein binding was assessed by ultrafiltration as previously described at three different timepoints per patient (1, 4 and 7.5 h). 24 Pharmacokinetic analysis Kinetica 3.0 (Innaphase, USA), computer software, was used to calculate pharmacokinetic parameters. Maximum plasma concentration (C max ), time to maximum plasma concentration (T max ), terminal elimination half-life (t1 =2 ) and area under the concentration-time curve from 0 to 7.5 h (AUC 0-7.5 ) were calculated from non-fitted data by employing the trapezoidal rule. For AUC 0-inf , individual extrapolation based on the last observed concentration and the elimination constant (k el ) was performed. Additionally, apparent total body clearance (CL) and apparent volume of distribution (V) were calculated for plasma.
In synovial fluid and muscle tissue T max synovial fluid , C max synovial fluid and AUC synovial fluid 0-7.5 and T max muscle , C max muscle and AUC muscle 0-7.5 were determined, respectively.
Pharmacokinetic/pharmacodynamic calculations and data analysis
For pharmacokinetic/pharmacodynamic calculations the ratio of free linezolid plasma AUC over MIC was used as previously recommended. 25 MIC 90 values for bacterial strains causing septic arthritis most frequently (i.e. S. aureus and S. epidermidis) were used. 26 In pharmacokinetic/pharmacodynamic calculations, CLSI breakpoints and MIC 90 values for clinical isolates of linezolid were used to warrant comparability. 26, 27 For plasma, optimal bactericidal killing may be expected if the AUC over MIC ratio is .50.
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Statistical analysis
Wilcoxon's paired tests were performed with SPSS 24 for MAC (IBM, USA) for statistical comparison of the main outcome pharmacokinetic parameter (AUC tissue to AUC free plasma ). All data are presented as mean + SD.
Results
This study included 10 subjects. Subject's characteristics are depicted in Table 1 . In this study, linezolid's ability to penetrate into synovial fluid and into soft tissue was evaluated by means of in vivo MD. All participants tolerated linezolid and the MD procedure well; no drug-related or serious adverse events occurred within the study period. In total, eight adverse events in seven subjects occurred. Seven subjects had post-surgical pain, and one subject had urinary retention. All adverse events were graded as mild and were not associated with the study drug, but either with the surgical procedure or with anaesthesia.
Relative recovery of linezolid was 22.5% and 18.9% in synovial fluid and muscle tissue, respectively. Linezolid plasma protein binding was relatively low with 12.0+2.6%, 12.7+1.7% and 12.6+2.8% after 2, 4 and 7.5 h of sampling, respectively. However, the values were comparable to values described in sepsis or septic shock patients (13.4%). Table 2 depicts the relevant main pharmacokinetic parameters. After a single infusion of 600 mg of linezolid, AUC 0-7.5 of 35.1+16.7, 47.2+39.3 and 46.8+11.3 mgÁh/L, in synovial fluid, muscle tissue and free plasma were achieved, respectively. While the difference between the free linezolid concentrations in plasma and muscle tissue was not significant (P " 0.25), the free linezolid concentration in plasma was significantly higher than in synovial fluid (P " 0.02). The mean ratios of the AUC 0-7.5 in tissues over the unbound AUC 0-7.5 in plasma were 0.76+0.34 and 0.98+0.62 for synovial fluid and muscle tissue, respectively. Table 3 shows the ratios of the AUC 0-24 to the MIC for pathogens with MICs of 1, 2 and 4 mg/L, respectively. After the equilibration period (i.e. after 90 min) mean plasma and tissue concentrations at individual timepoints correlated well for synovial fluid (R " 0.80, P " 0.02) and muscle tissue (R " 0.99, P , 0.01) (Figure 2 ).
Discussion
Overall, linezolid has been used as a treatment of joint infections for many years with high clinical success rates, but data enabling the appropriate description of pharmacokinetic/pharmacodynamic indices were lacking. 30 In this study, the unbound concentration of linezolid in plasma, synovial fluid and the interstitial space fluid of muscle tissue were assessed after knee arthroscopy. By successful implantation of MD probes into the synovial cavity after surgery the unbound fraction of linezolid was continuously measured inside the synovial cavity for the first time. 27 Large-scale susceptibility surveillance trials described MIC 90 values of linezolid for S. aureus and CoNS as 2 and 1 mg/L, respectively. 26 Although only well established for plasma for linezolid the AUC/ MIC 0-24 ratio is regarded as the most important pharmacokinetic/ pharmacodynamic parameter to predict treatment outcome. The best outcome can be expected for AUC/MIC 0-24 ratios in plasma !50. 31 In synovial fluid linezolid's AUC 0-24 /MIC ratios for bacterial strains with an MIC of 1, 2 and 4 mg/L were 86.8+47.0, 43.4+23.5 and 21.7+11.8, respectively. Accordingly, the optimal treatment effect of linezolid in septic arthritis might only be expected against strains with an MIC of 1 mg/L, but not for S. aureus strains with an MIC of up to 4 mg/L, which, at least according to CLSI, would be susceptible. It must, however, be emphasized that by only doubling the AUC 0-12 after the first administration the estimated AUC 0-24 is very conservative and might be higher, particularly on subsequent treatment days.
After the equilibration period, unbound concentration versus time profiles in all three investigated compartments were comparable (Figure 1) . However, the protein binding of linezolid in plasma was determined by ultrafiltration only at certain timepoints and therefore must be considered an estimation. Owing to the methodological advantage of MD in synovial fluid and muscle tissue, only the free fraction of linezolid was measured directly and therefore no further correction for protein binding was necessary.
Flushing the joint during arthroscopy dilutes the synovial fluid within the joint cavity. This may have an influence on the protein levels of synovial fluid and linezolid concentrations measured in this study. However, drainage was implanted into the joint cavity after arthroscopy. Synovial membranes continuously secrete synovial fluid as an ultrafiltrate from plasma. We therefore suspect that after arthroscopy, flushing fluid was removed rapidly from the joint cavity and replaced by synovial fluid thereby minimizing the effects of synovial fluid dilution.
Although protein levels in synovial fluid are of interest, neither protein levels nor protein binding of linezolid in synovial fluid were measured within this study. Since the mean protein level in synovial fluid of $44 g/L 32 is expected to be lower than in plasma and the composition of the protein mix might be different, protein binding in synovial fluid cannot be judged without direct determination. However, for other antibiotics, protein binding in synovial fluid was shown to be relatively low compared with plasma, e.g. in the case of ampicillin, protein binding in synovial fluid was found to be $5%. 33 Interestingly, in this study, linezolid peak concentration and AUC in plasma (C max 15.5+7.6 mg/L, AUC 0-7.5 46.8+11.3 mgÁh/L) were similar to those described in other studies (C max 12.84+2.57 mg/L, AUC 0-7.5 52.98+11.78 mgÁh/L), but t1 =2 (3.3+0.5 h) was considerably shorter than described in other studies (t1 =2 4.73+2.08 h). 25, 34, 35 In the present study subjects received 2.0+0.6 L of fluid during surgery. We suspect that increased diuresis after surgery might have caused an increase in plasma clearance and thereby shortened t1 =2 . Moreover, patients in this study were operated on under general anaesthesia. General anaesthesia has been shown to induce several enzymatic reactions that may accelerate degradation of Schwameis et al.
antibiotic compounds. However, linezolid is mainly degraded by enzyme-independent oxidation; therefore, accelerated degradation of linezolid by enzymatic induction is unlikely. Rana et al. 36 measured linezolid concentrations in synovial fluid during total knee replacement by direct sampling 30 min after induction of anaesthesia. While no further details with regard to dosing are described, the authors state that linezolid synovial fluid concentrations at steady-state were 91.9%+23.8% of the corresponding plasma concentrations, which is of the same magnitude as penetration into synovial fluid observed in the present study as reflected by an AUC synovial fluid /AUC free plasma ratio of 0.76+0.34. As previously observed, the tissue-penetration ability of linezolid was highly variable between subjects. In this study, slightly lower penetration of linezolid into muscle tissue (AUC muscle /AUC free plasma 0.98+0.62) was observed, than previously described (1.3+0.4). 29 Currently, the value of perioperative antibiotic prophylaxis when performing arthroscopy in uncomplicated patients is subject to discussion. 37, 38 In has to be pointed out, that subjects in this study received linezolid solely to measure clinical pharmacokinetic parameters and not with any curative or prophylactic intent.
A limitation of the present study is that linezolid concentrations were investigated in non-infected knees. A study comparing linezolid tissue concentrations in septic patients with healthy volunteers concluded that tissue concentrations in both groups were similar with slightly higher linezolid tissue concentrations in healthy subjects. 25 Local tissue inflammation has been shown to dampen the activity of macrolides, but not b-lactam antibiotics. However, the effect of local tissue inflammation on linezolid pharmacokinetics has not been sufficiently investigated up to now.
To the best of our knowledge, this is the first study to measure continuously the pharmacokinetics of an antibiotic agent inside the synovial cavity by use of MD. Intra-articular MD is feasible, without any relevant discomfort for the patients and yields a new opportunity to measure target-site concentrations. Our data suggest that intraarticular concentrations of linezolid might be optimal for treatment of bacterial strains with an MIC 90 of 1 mg/L. When treating strains with an MIC .1 mg/L, frequent treatment surveillance is therefore recommended. Knee microdialysis of linezolid JAC
